LABORATORY REPORT

Redcliffe labs

Patient NAME			
DOB/Age/Gender	Report STATUS		
Patient ID / UHID	Barcode NO		
Referred BY	Sample Type		
Sample Collected	Report Date		

ilac-MRA MC-5280

Test Description	Value(s)	Unit(s)	Reference Range

Anti Mullerian Hormone (AMH)

ANTI MULLERIAN HORMONE; AMH,SERUM *CLIA*	3.2	ng/mL	0.17 - 7.37

Interpretation:

AMH LEVEL IN ng/mL	Remarks
<0.50	Predictive of poor response
0.50 - <1.0	Suggestive of limited ovarian reserve
1.00 - 3.50	Predictive of optimal response
>3.50	Predictive of Ovarian hyperstimulation syndrome/PCOS

Notes

1. AMH stars declining years prior to rise in FSH thus it is much more sensitive marker of ovarian reserve.
2. Discordant results between AMH and antral follicle count (AFC) may be observed as AMH reflects population of preantral follicles whereas AFC measures only those visualized-on USG

Comment

Antimullerian hormone (AMH), also known as mullerian-inhibiting substance is produced by Sertoli cells of the testis in males and by ovarian granulosa cells in females. In males, AMH serum concentrations are elevated under 2 years and then progressively decrease until puberty, when there is a sharp decline. In females, AMH is produced by the granulosa cells of small growing follicles from the 36th week of gestation onwards until menopause when levels become undetectable. Due to the gender differences in AMH concentrations, its changes in circulating concentrations with sexual development, and its specificity for Sertoli and granulosa cells, measurement of AMH has utility in the assessment of gender, gonadal function, fertility, and as a gonadal tumor marker. Since AMH is produced continuously in the granulosa cells of small follicles during the menstrual cycle, it is superior to the episodically released gonadotropins and ovarian steroids as a marker of ovarian reserve. Studies in fertility clinics have shown that females with higher concentrations of AMH have a better response to ovarian stimulation and tend to produce more retrievable oocytes than females with low or undetectable AMH. Females at risk of ovarian hyperstimulation syndrome after gonadotropin administration can have significantly elevated AMH concentrations. Polycystic ovarian syndrome can elevate serum AMH levels because it is associated with the presence of large numbers of small follicles. Serum AMH levels are increased in some patients with ovarian granulosa cell tumors, which comprise approximately 10% of ovarian tumors.

Clinical applications

1. To assess ovarian status, including follicle development, ovarian reserve, and ovarian responsiveness, as part of evaluation for infertility and assisted reproduction protocols.
2. To assess menopausal status, including premature ovarian failure.
3. To assess ovarian function in patients with Polycystic ovarian syndrome (PCOS).
4. To evaluate infants with ambiguous genitalia and other intersex conditions.
5. To evaluate testicular function in infants and children
6. To diagnose and monitor patients with AMH secreting Ovarian granulosa cell tumors.

*** End Of Report ***

Dr. Poulami Sarkar
MBBS,MD (Biochemistry)
Consultant Biochemist
NMC Certificate No. 24-005955

Terms and Conditions of Reporting

1. The presented findings in the Reports are intended solely for informational and interpretational purposes by the referring physician or other qualified medical professionals possessing a comprehensive understanding of reporting units, reference ranges, and technological limitations. The laboratory shall not be held liable for any interpretation or misinterpretation of the results, nor for any consequential or incidental damages arising from such interpretation.

2. It is to be presumed that the tests performed pertain to the specimen/sample attributed to the Customer's name or identification. It is presumed that the verification particulars have been cleared out by the customer or his/her representation at the point of generation of said specimen / sample. It is hereby clarified that the reports furnished are restricted solely to the given specimen only.

3. It is to be noted that variations in results may occur between different laboratories and over time, even for the same parameter for the same Customer. The assays are performed and conducted in accordance with standard procedures, and the reported outcomes are contingent on the specific individual assay methods and equipment(s) used, as well as the quality of the received specimen.

4. This report shall not be deemed valid or admissible for any medico-legal purposes.

5. The Customers assume full responsibility for apprising the Company of any factors that may impact the test finding. These factors, among others, includes dietary intake, alcohol, or medication / drug(s) consumption, or fasting. This list of factors is only representative and not exhaustive.

DISCLAIMER

This is a sample report provided for demonstration purposes only and does not represent an actual patient report. Test results, reference ranges, methodologies, instrumentation, and report formats may vary depending on the laboratory performing the test. The format and representation shown are indicative of reports generated by the National Reference Laboratory of Redcliffe Labs, Noida. This sample report should not be used for medical interpretation, diagnosis, or treatment decisions.